Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants

Open to people ages 18-80

• Has stable primary dilated cardiomyopathy due to either MYH7 or TTN variant
• Has adequate acoustic windows for echocardiography
• Maximum of 3 family members with same variant can be enrolled

• Significant structural cardiac abnormalities including valvar dysfunction on Screening transthoracic echo(s)
• A pathogenic variant implicated in DCM of another gene other than MYH7 or TTN
• Routinely scheduled outpatient intravenous (IV) infusions for heart failure (e.g., inotropes, afterload reduction, or diuretics)
• Presence of protocol specified laboratory abnormalities at Screening
• Recent acute coronary syndrome or angina pectoris (<90 days)
• Recent hospitalization for heart failure (<90 days)